XTAE
EFNC-M
Market cap2mUSD
Aug 15, Last price
261.30ILS
Name
Erech Finance Cahalacha Ltd
Chart & performance
P/E
—
P/S
23.51
EPS
—
Div yield, %
—
Shrs. gr., 5y
15.94%
Rev. gr., 5y
-50.83%
Revenues
282k
-97.35%
Net income
-25m
L+1.01%
CFO
-2m
L-53.88%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Erech Finance Cahalacha Ltd, including its subsidiaries, provides diverse lending and credit solutions to small and medium-sized businesses, associations, and individual clients across Israel. The company's operations are structured into two main divisions: Non-Bank Credit and Biomed Drug. Additionally, Erech Finance Cahalacha Ltd is engaged in pharmaceutical research and development, concentrating on treatments for diabetes and cancer. Its corporate headquarters are located in Jerusalem, Israel.
Key people
Eliyahu Naor
Chairman of the Board · since 2018
Vice President - Finance · since 2019
Internal Auditor · since 2015
Avinoam Ben Nun
Director · since 2019
Ziv Eisner
Director · since 2017
Avraham Sarfaty
Director · since 2018
Yosef Wasserman
Co-Chief Executive Officer, Director · since 2018
Michael Kenig
External Director · since 2019
Sharon Teperberg
External Director · since 2019
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||